

---

# Kluwer Patent Blog

## Patent case: Regeneron Pharmaceuticals v Kymab, United Kingdom

Sara Moran · Thursday, August 16th, 2018

Following the Court of Appeal's decision that two of Regeneron's patents were valid and infringed, it refused to grant Kymab permission to appeal to the Supreme Court, but held that the injunction against Kymab should be stayed, subject to certain conditions, whilst Kymab applied directly to the Supreme Court for permission to appeal. The Court also gave directions on the scope of orders for delivery up or destruction of infringing goods, disclosure of information on Kymab's infringing products, and costs.

Case date: 23 May 2018

Case number: [2018] EWCA Civ 1186

Court: Court of Appeal of England and Wales, Civil Division

A full summary of this case has been published on [Kluwer IP Law](#).

---

*To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please [subscribe here](#).*

### Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

---

79% of the lawyers think that the importance of legal technology will increase for next year.

**Drive change with Kluwer IP Law.**

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT  
The Wolters Kluwer Future Ready Lawyer  
Leading change



This entry was posted on Thursday, August 16th, 2018 at 1:59 am and is filed under [Case Law](#), [Pharma](#), [United Kingdom](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.